gancotamab

Gancotamab (MM-302) is a novel HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate developed for the treatment of HER2-overexpressing cancers. It consists of an anti-HER2 single-chain variable fragment (scFv), known as F5, covalently linked to the surface of a PEGylated liposome containing doxorubicin. The scFv targets the HER2 receptor on cancer cells, facilitating the internalization of the liposome via endocytosis and the subsequent release of doxorubicin within the tumor cell. This targeted delivery mechanism is designed to maximize the uptake of the cytotoxic payload by cancer cells while minimizing systemic exposure and the cardiotoxicity typically associated with free anthracyclines. Developed by Merrimack Pharmaceuticals, gancotamab was primarily investigated for advanced HER2-positive breast cancer. However, development was discontinued in late 2016 following the Phase 2 HERMIONE trial, which failed to demonstrate a significant benefit over the physician's choice of treatment.

Other names

MM-302MM302MM 302HER2-targeted PEGylated antibody-liposomal doxorubicin conjugateHER-2-targeted PEGylated antibody-liposomal doxorubicin conjugateHER 2-targeted PEGylated antibody-liposomal doxorubicin conjugate64Cu-MM-302